The American Recovery and Reinvestment Act of 2009 provided $1.1 billion for comparative effectiveness research (CER). The Patient Protection and Affordable Care Act established the Patient-Centered ...

The US House of Representatives is considering legislation (HR 485) that would prohibit the use of the quality-adjusted life-year (QALY) and similar measures for coverage and payment determinations ...

Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...

Understanding the clinical nuances of when and to whom services render the greatest benefit requires more research. The type of research that addresses this issue is commonly labeled comparative ...

Five Republican Senators have reintroduced a bill to bar the federal government from undertaking comparative effectiveness research, according to a release by Senator Mike Crapo (R-Idaho). The 2009 ...

If there was one place research should be easy to perform, it’s on a disease that’s incredibly common. Further, if there are two generally-accepted strategies to treating symptomatic patients with ...

The research results must avoid creating unintended access barriers, coverage denials, or arbitrary dollar thresholds that can arise through centralized cost effectiveness determinations. By focusing ...

The Patient-Centered Outcomes Research Institute (PCORI) today announced funding awards totaling $208 million to support 17 new comparative clinical effectiveness research (CER) studies, including ...

Comparative effectiveness research, a proposed method to cut health care spending, is sharply criticized in a new report identifying numerous negative ramifications of the policy. The report, “Shorter ...

PCORI also is offering up to $200 million through the Phased Large Awards for Comparative Clinical Effectiveness Research (PLACER) PFA, for ambitious, large-scale two-phased trials addressing critical ...

Comparative effectiveness research is under attack as a new way to limit access to the best health care. Nothing could be further from the truth—in fact, it’s the exact opposite. Comparative ...